Cosmos Health Seeks Reverse Split, Massive Share Increase at Annual Meeting

TL;DR

**COSM is gearing up for a reverse stock split and a massive share authorization increase, signaling potential dilution and a desperate attempt to stay listed – tread carefully.**

AI Summary

Cosmos Health Inc. is holding its 2025 Annual Meeting of Stockholders on September 30, 2025, to address several critical proposals impacting its corporate structure and financial future. Key proposals include the election of six directors, authorization for a reverse stock split, and approval for the issuance of common stock related to note conversions, which is crucial for compliance with Nasdaq Listing Rule 5635(d). The company also seeks approval for its 2025 equity incentive plan and an amendment to its Articles of Incorporation to significantly increase authorized capital stock to 1,500,000,000 shares of Common Stock and 300,000,000 shares of "blank check" Preferred Stock. Additionally, stockholders will cast non-binding advisory votes on executive compensation and the frequency of future 'Say on Pay' votes. The Board of Directors unanimously recommends voting 'FOR' all proposals, emphasizing their belief that these actions are in the best interest of the company and its stockholders.

Why It Matters

Cosmos Health's proposals, particularly the potential reverse stock split and the dramatic increase in authorized shares to 1.5 billion common and 300 million preferred, could significantly impact investor holdings and the company's future capital-raising capabilities. A reverse split often signals efforts to meet exchange listing requirements but can also dilute existing shareholder value if not managed carefully. The approval of new equity for note conversions and a 2025 incentive plan suggests a need for capital and a focus on executive and employee retention, which could be a competitive advantage or a source of dilution. Investors need to understand these changes to assess the long-term viability and potential returns of their investment in COSM.

Risk Assessment

Risk Level: high — The proposal to authorize the Board to effect a reverse stock split (Proposal 2) and the request to increase authorized shares to 1,500,000,000 Common Stock and 300,000,000 Preferred Stock (Proposal 8) indicate significant potential for dilution and a high risk of delisting if the reverse split is intended to boost share price for Nasdaq compliance. These actions often precede further capital raises that can heavily dilute existing shareholders.

Analyst Insight

Investors should carefully review the implications of the proposed reverse stock split and the substantial increase in authorized shares. Consider voting against proposals that could lead to excessive dilution without clear, immediate benefits, and evaluate the company's historical performance and current financial health before the September 30, 2025 meeting.

Key Numbers

• 30,127,379 — Shares of Common Stock issued and outstanding (As of August 1, 2025 (Record Date))
• 1,500,000,000 — Proposed authorized shares of Common Stock (Significant increase from current levels, indicating potential for substantial future dilution)
• 300,000,000 — Proposed authorized shares of 'blank check' Preferred Stock (New authorization for preferred stock, offering flexibility for future capital raises or strategic transactions)
• September 30, 2025 — Date of Annual Meeting (Key date for stockholder decisions on critical proposals)
• August 1, 2025 — Record Date for voting (Determines which stockholders are eligible to vote at the Annual Meeting)

Key Players & Entities

• Cosmos Health Inc. (company) — Registrant and subject of the DEF 14A filing
• Grigorios Siokas (person) — Chairman and Chief Executive Officer of Cosmos Health Inc.
• Nasdaq Listing Rule 5635(d) (regulator) — Rule governing the issuance of shares upon conversion of notes
• Equiniti (company) — Company's transfer agent
• Securities and Exchange Commission (regulator) — Regulator overseeing proxy materials
• $1,500,000,000 (dollar_amount) — Proposed maximum aggregate value of transaction (implied for authorized shares)
• Chicago, IL (location) — Location of the Annual Meeting
• Thessaloniki, Greece (location) — Location of Cosmos Health Inc.'s principal executive offices

FAQ

Risk Factors

• Significant Increase in Authorized Capital Stock [high — financial]: The company is seeking to increase authorized common stock to 1,500,000,000 shares and preferred stock to 300,000,000 shares. This substantial increase from current levels, with 30,127,379 shares outstanding as of August 1, 2025, creates a high potential for future dilution of existing shareholders' equity.
• Compliance with Nasdaq Listing Rule 5635(d) [medium — regulatory]: The company requires stockholder approval for the issuance of common stock upon conversion of notes to comply with Nasdaq Listing Rule 5635(d). Failure to secure this approval could lead to non-compliance with exchange rules.
• Reverse Stock Split Authorization [medium — financial]: The company is seeking authorization for a reverse stock split. While not specifying a ratio, this action is often taken to increase the per-share trading price, which can be a precursor to avoiding delisting or facilitating future financing.
• Equity Incentive Plan Approval [medium — financial]: Approval of the 2025 Equity Incentive Plan allows for the issuance of new equity awards. This can lead to further dilution if not managed carefully, impacting the value of existing shares.

Industry Context

Cosmos Health operates within the pharmaceutical and healthcare sector, a highly competitive and regulated industry. Key trends include increasing demand for specialized treatments, evolving regulatory landscapes, and the ongoing pressure to innovate and manage costs effectively. Companies in this space often rely on strategic partnerships, R&D, and efficient supply chain management to maintain market position.

Regulatory Implications

The company faces regulatory scrutiny related to Nasdaq listing rules, specifically Rule 5635(d), which requires shareholder approval for certain share issuances. Additionally, the proposed increase in authorized capital stock and the potential reverse stock split are actions that require careful management to maintain investor confidence and compliance.

What Investors Should Do

1. Review the proposed increase in authorized shares (1.5 billion common, 300 million preferred) and understand the potential for dilution.
2. Evaluate the necessity and potential impact of the proposed reverse stock split.
3. Understand the rationale behind the approval needed for share issuance under Nasdaq Listing Rule 5635(d).
4. Consider the implications of the 2025 Equity Incentive Plan on future share dilution.

Key Dates

• 2025-09-30: 2025 Annual Meeting of Stockholders — Stockholders will vote on critical proposals including director elections, reverse stock split, equity incentive plan, and amendments to authorized capital stock.
• 2025-08-01: Record Date for voting eligibility — Determines which stockholders are eligible to vote at the Annual Meeting on September 30, 2025.
• 2025-08-25: First mailing of Proxy Statement and 2024 Annual Report — Informs stockholders about the meeting agenda and provides necessary information for voting decisions.

Glossary

DEF 14A

A proxy statement filed with the U.S. Securities and Exchange Commission (SEC) by publicly traded companies. It contains detailed information about matters to be voted on at an annual or special meeting of shareholders. (This document is the primary source of information for the analysis, detailing the company's proposals and financial context.)

Reverse Stock Split

A corporate action in which a company reduces the total number of its outstanding shares by consolidating them. This typically increases the per-share price. (Cosmos Health is proposing this action, which could impact share price and investor perception.)

'Blank Check' Preferred Stock

A class of preferred stock that has not been assigned specific rights, powers, and privileges. The board of directors is authorized to determine these details later, offering flexibility for future financing or strategic actions. (The company seeks to authorize 300,000,000 shares of this type, indicating a strategy for future capital raising or corporate restructuring.)

Nasdaq Listing Rule 5635(d)

A rule requiring shareholder approval for the issuance of securities in connection with the acquisition of the assets or businesses of another company, or when the issuance involves the sale or potential sale by the company of common stock (or securities convertible into common stock) at a price below the Minimum Bid Price (as defined in the rule), if the number of shares of common stock to be issued equals or exceeds 20% of the common stock then outstanding. (Cosmos Health needs approval for share issuance related to note conversions to comply with this rule.)

Equity Incentive Plan

A plan that allows a company to grant stock options, restricted stock, or other equity-based awards to employees, directors, and consultants. (The company is seeking approval for its 2025 Equity Incentive Plan, which will affect future share count and employee compensation.)

Say on Pay Vote

A non-binding shareholder vote on the compensation of a company's top executives. (Stockholders will have an advisory vote on executive compensation and the frequency of these votes.)

Year-Over-Year Comparison

This filing indicates a significant shift in corporate strategy compared to previous periods, focusing on substantial capital structure changes. The key proposals for increasing authorized shares, implementing a reverse stock split, and approving equity incentive plans suggest a proactive approach to future financing and operational needs, which may differ from the focus of the prior year's filings.

Filing Documents

• cosm_def14a.htm (DEF 14A) — 727KB
• cosm_def14aimg1.jpg (GRAPHIC) — 22KB
• cosm_def14aimg2.jpg (GRAPHIC) — 21KB
• 0001477932-25-006195.txt ( ) — 787KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 16 Summary Compensation Table 17 Narrative Disclosure to Summary Compensation Table 17 Outstanding Equity Awards At Year-End 18

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 22 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 23 AUDIT COMMITTEE REPORT 25 PROPOSAL 2 - AUTHORIZATION OF THE BOARD OF DIRECTORS TO AMEND THE ARTICLES OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE COMPANY'S OUTSTANDING COMMON STOCK AT THEIR DISCRETION 26 PROPOSAL 3 - APPROVAL OF THE ISSUANCE OF SHARES OF COMMON STOCK ISSUABLE UPON THE CONVERSION OF THE NOTES IN COMPLIANCE WITH NASDAQ LISTING RULE 5635(D) 33 PROPOSAL 4 - RATIFICATION OF THE APPOINTMENT OF THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 36 PROPOSAL 5 - APPROVAL OF THE COMPANY'S 2025 EQUITY INCENTIVE PLAN 37 PROPOSAL 6 - THE NON-BINDING ADVISORY SAY ON PAY VOTE 43 PROPOSAL 7 - THE NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF THE FUTURE SAY ON PAY VOTES 44 PROPOSAL 8 – APPROVAL OF THE AMENDMENT TO THE COMPANY'S ARTICLES OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF CAPITAL STOCK OF THE COMPANY TO 1,500,000,000 SHARES OF COMMON STOCK AND 300,000,000 SHARES OF "BLANK CHECK" PREFERRED STOCK 45 OTHER INFORMATION 46 4 Table of Contents COSMOS HEALTH INC. PROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD AT THE COMPANY'S U.S. HEADQUARTERS, 141 WEST JACKSON BOULEVARD, SUITE 4234, CHICAGO, IL 60604 SEPTEMBER 30, 2025 GENERAL INFORMATION Our Board of Directors (the "Board") solicits your proxy on our behalf for the 2025 Annual Meeting of Stockholders (the "Annual Meeting") of Cosmos Health Inc. and at any postponement or adjournment of the Annual Meeting for the purposes set forth in this Proxy Statement and the accompanying Notice of 2025 Annual Meeting of Stockholders (the "Notice"). The Annual Meeting will be held at 9:00 A.M. (Central Time) on September 30, 2025. You will be able to attend the Annual Meeting, vote and submit your questions at the Annual Meeting. In this Proxy Statement the terms "Cos

View Full Filing

View this DEF 14A filing on SEC EDGAR